LeadIQ logo
Learn more at LeadIQ.com

Insights

Innovative Therapies 89bio focuses on developing innovative therapies for liver and cardio-metabolic diseases, offering potential solutions to unmet medical needs in these areas.

Financial Stability With $440.0 million in cash, cash equivalents, and marketable securities as of December 31, 2024, following a recent gross proceeds addition of $287.5 million, 89bio is financially robust, indicating a strong position for potential collaborations or investments.

Clinical Progress 89bio's lead product candidate, BIO89-100, has shown promising clinical results in reducing liver fat and key lipid markers for patients with NASH and SHTG. This progress can be leveraged to attract partnerships or expand market reach.

Market Interest Analysts suggest a potential upside of 171.42% in 89bio's stock, indicating positive market sentiment and growth potential that can attract investor interest and lead to business expansion opportunities.

Fostering Relationships Participation in key industry conferences like the Leerink Partners Global Healthcare Conference provides 89bio with valuable networking opportunities to engage with potential collaborators, investors, and customers.

89bio Tech Stack

89bio uses 8 technology products and services including W3 Total Cache, Amazon Web Services, Cloudflare CDN, and more. Explore 89bio's tech stack below.

  • W3 Total Cache
    Caching
  • Amazon Web Services
    Cloud Hosting
  • Cloudflare CDN
    Content Delivery Network
  • NetSuite
    E-commerce
  • jQuery
    Javascript Libraries
  • Microsoft Word
    Office Suites
  • PHP
    Programming Languages
  • Bootstrap
    UI Frameworks

Media & News

89bio's Email Address Formats

89bio uses at least 1 format(s):
89bio Email FormatsExamplePercentage
First.Last@89bio.comJohn.Doe@89bio.com
50%
First.Last@89bio.comJohn.Doe@89bio.com
50%

Frequently Asked Questions

Where is 89bio's headquarters located?

Minus sign iconPlus sign icon89bio's main headquarters is located at San Francisco, CA US. The company has employees across 4 continents, including North AmericaAsiaEurope.

What is 89bio's stock symbol?

Minus sign iconPlus sign icon89bio is a publicly traded company; the company's stock symbol is ETNB.

What is 89bio's official website and social media links?

Minus sign iconPlus sign icon89bio's official website is 89bio.com and has social profiles on LinkedIn.

How much revenue does 89bio generate?

Minus sign iconPlus sign icon As of March 2025, 89bio's annual revenue reached $3.8M.

What is 89bio's SIC code NAICS code?

Minus sign iconPlus sign icon89bio's SIC code is 8733 - Noncommercial Research Organizations NAICS code is 541714 - Research and Development in Biotechnology (except Nanobiotechnology).

How many employees does 89bio have currently?

Minus sign iconPlus sign iconAs of March 2025, 89bio has approximately 129 employees across 4 continents, including North AmericaAsiaEurope. Key team members include Chief Operating Officer: F. S.Chief Financial Officer: R. M.Chief Medical Officer: H. M.. Explore 89bio's employee directory with LeadIQ.

What industry does 89bio belong to?

Minus sign iconPlus sign icon89bio operates in the Biotechnology Research industry.

What technology does 89bio use?

Minus sign iconPlus sign icon89bio's tech stack includes W3 Total CacheAmazon Web ServicesCloudflare CDNNetSuitejQueryMicrosoft WordPHPBootstrap.

What is 89bio's email format?

Minus sign iconPlus sign icon89bio's email format typically follows the pattern of . Find more 89bio email formats with LeadIQ.

How much funding has 89bio raised to date?

Minus sign iconPlus sign icon As of March 2025, 89bio has raised $250M in funding. The last funding round occurred on Jan 28, 2025 for $250M.

When was 89bio founded?

Minus sign iconPlus sign icon89bio was founded in 2018.
89bio

89bio

Biotechnology ResearchCalifornia, United States51-200 Employees

89bio is a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of liver and cardio-metabolic diseases. The company’s lead product candidate, BIO89-100, is a specifically engineered glycoPEGylated analog of FGF21. BIO89-100 is being developed for the treatment of nonalcoholic steatohepatitis (NASH) and severe hypertriglyceridemia (SHTG). Recent Phase 1b/2a data show BIO89-100 demonstrated a favorable safety and tolerability profile and robust reductions in liver fat and key lipid markers when dosed weekly or once every two weeks in patients with NASH. BIO89-100 is currently in a Phase 2 trial for the treatment of SHTG. 89bio is headquartered in San Francisco with operations in Herzliya, Israel.

Our culture is best described by our values:
•	Always putting the patient first
•	Operating with the highest integrity and ethical standards at all times
•	Being authentic in all our transactions
•	Acting as a team – collaborating, respecting and caring for one another
•	Being entrepreneurial and passionate in our tasks
•	Being scientific and rational in our thought process and decision-making

Section iconCompany Overview

Headquarters
San Francisco, CA US
Website
89bio.com
SIC Code
8733 - Noncommercial Research Organizations
Stock Symbol
ETNB
NAICS Code
541714 - Research and Development in Biotechnology (except Nanobiotechnology)
Founded
2018
Employees
51-200

Section iconMedia & News

Section iconFunding & Financials

  • $250M

    89bio has raised a total of $250M of funding over 9 rounds. Their latest funding round was raised on Jan 28, 2025 in the amount of $250M.

  • $10M

    89bio's revenue is in the range of $10M

Section iconFunding & Financials

  • $250M

    89bio has raised a total of $250M of funding over 9 rounds. Their latest funding round was raised on Jan 28, 2025 in the amount of $250M.

  • $10M

    89bio's revenue is in the range of $10M

Company Leadership

  • Stylized image of a person
    F. S.
    Chief Operating Officer
    Phone icon
    Mobile Phone
  • Stylized image of a person
    R. M.
    Chief Financial Officer
    Phone icon
    Mobile Phone
  • Stylized image of a person
    H. M.
    Chief Medical Officer
    Phone icon
    Mobile Phone
  • Stylized image of a person
    Q. L.
    Chief Technical Operations Officer & Head Of Quality
    Phone icon
    Mobile Phone
  • Stylized image of a person
    Q. L.
    Chief Technical Operations Officer And Head Of Quality
    Phone icon
    Mobile Phone

Employee Directory

  • Stylized image of a person
    H. K.
    Executive Assistant To Chief Executive Officer
    Phone icon
    Mobile Phone
  • Stylized image of a person
    Q. L.
    Chief Technical Operations Officer And Head Of Quality
    Phone icon
    Mobile Phone
  • Stylized image of a person
    J. M.
    Head Of Talent Acquisition
    Phone icon
    Mobile Phone
  • Stylized image of a person
    M. R.
    Vice-President, Preclinical Development
    Phone icon
    Mobile Phone
  • Stylized image of a person
    A. C.
    Vice President, Investor Relations & Corporate Communications
    Phone icon
    Mobile Phone

Ready to create more pipeline?

Get a demo and discover why thousands of SDR and Sales teams trust LeadIQ to help them build pipeline confidently.

Ready to create more pipeline?

Get a demo and discover why thousands of SDR and Sales teams trust
LeadIQ to help them build pipeline confidently.

© LeadIQ, Inc. All rights reserved.